No Data
JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination With Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
"Expanding through AI! Complete DX"
Otsuka Corporation, a solution provider headquartered in Chiyoda, Tokyo, with President Hiroshi Otsuka, will hold the "Practical Solution Fair 2025" in February 2025 in Tokyo, Osaka, and online. Registration for the event will be available on our website starting from December 16, 2024. This is the 48th "Practical Solution Fair", held annually as a platform to embody our mission of "Revitalizing the office with IT."
Announcement of individual stocks: Revenue has exceeded 1 trillion yen.
Otsuka Corporation (Headquarters: Chiyoda, Tokyo, Representative Director and President: Yuji Otsuka) is currently in the consolidated accounting period for the fiscal year ending December 2024 (January 1, 2024 - December 31, 2024), and we are pleased to announce that we have surpassed a consolidated revenue of 1 trillion yen for the first time since our founding. The consolidated revenue plan for the fiscal year ending December 2024, which was disclosed on August 1, 2024, is 1 trillion 55 billion yen, and we will continue to work towards achieving this target. This achievement is entirely thanks to our customers.
Lion, Kobayashi Pharmaceutical, etc (additional) Rating
Target stock price change code stock name securities company previous changed after --------------------------------------------- <2607> Fuji Oil SMBC Nikko 3800 yen 4200 yen <2802> Ajinomoto SMBC Nikko 6800 yen 7200 yen <4043> Tokuyama Mizuho 3200 yen 3300 yen <4183> Mitsui Chemicals Nomura 4500 yen 4730 yen <4506> Sumitomo Pharma SMBC Nikko 600 yen 650 yen <4552> JCR Pharma
Otsuka Completes Share Repurchase Program
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia